Bavarian Nordic A/S appointed Dr. Christopher R. Heery to the role of chief medical officer for the company on Wednesday.
Heery will manage the preclinical and clinical development of Bavarian Nordic’s infectious disease and immune-oncology portfolio. His position is based on the east coast of the United States, and will report directly to the company’s President and Chief Executive Officer Paul Chaplin.
“It is with great pleasure that I welcome Chris to Bavarian Nordic,” Chaplin said. “Through our collaborations with the NCI, Chris developed an exceptional understanding of our programs and our science, which draws from his experience leading key clinical trials in immunology and oncology. Chris will serve as an essential member of the team as we continue to progress our pipeline of immune-oncology and infectious disease vaccine candidates.”
Prior to his new appointment, Heery was the director of the clinical trials group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). Heery also served as an adjunct appointment in the genitourinary malignancies branch with NCI. During his time with the organization, Heery assisted in the development of new immunotherapies for the treatment of cancer.
“I am pleased to join Bavarian Nordic and look forward to continuing to build the Company’s core collaborations and advancing its portfolio of promising immunotherapies across multiple challenging disease areas with the potential to significantly impact patient care,” Heery said.